Research programme: gene modulating therapeutics - Scenic Biotech
Alternative Names: Disease modifying therapeutics - Scenic BitoechLatest Information Update: 09 Feb 2023
At a glance
- Originator Scenic Biotech
- Class Gene therapies
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Barth syndrome; Metabolic syndrome; Niemann-Pick disease type C
Most Recent Events
- 02 Feb 2023 Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Niemann-Pick Type C Disease
- 30 Mar 2022 Scenic Biotech and the Barth Syndrome Foundation agree to co-develop gene modulating therapeutics in USA for Barth syndrome
- 09 Mar 2022 Research programme: gene modulating therapeutics - Scenic Biotech is available for licensing as of 09 Mar 2022. https://scenicbiotech.com/programs/ 9351770